Express Scripts Eyes New Price War: Anti-PCSK9 Drugs
Regeneron Pharmaceuticals reported solid Q4 sales, but the big cap biotech’s stock reversed lower Tuesday as its potentially huge new cholesterol fighter was in the crosshairs of a leading pharmacy benefit manager (PBM). At the JPMorgan Healthcare Conference in San Francisco, Express Scripts (ESRX) CEO George Paz chatted at a Q&A session about his company’s recent success at driving discounts to pricey new hepatitis C drugs by